key: cord-1047429-gscskz2z
authors: Hagin, David; Freund, Tal; Navon, Michal; Halperin, Tami; Adir, Dikla; Marom, Rotem; Levi, Inbar; Benor, Shira; Alcalay, Yifat; Freund, Natalia T.
title: Immunogenicity of Pfizer-BioNTech COVID-19 Vaccine in Patients with Inborn Errors of Immunity.
date: 2021-06-01
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2021.05.029
sha: ee12bbd9d4df2b5d2a4b2bb6f725ae3ffa12df92
doc_id: 1047429
cord_uid: gscskz2z

Background In mid-December 2020, Israel had started a nationwide mass vaccination campaign against COVID-19. In the first few weeks, medical personnel, elderly citizens and patients with chronic diseases were prioritized. As such, patients with primary and secondary immunodeficiencies were encouraged to receive the vaccine. While the efficacy of RNA-based COVID-19 vaccines was demonstrated in the general population, little is known about their efficacy and safety in patients with Inborn Errors of Immunity (IEI). Objectives To evaluate the humoral and cellular immune response to COVID-19 vaccine in a cohort of IEI patients. Methods 26 adult patients were enrolled, and plasma and peripheral blood mononuclear cells were collected two weeks following the second dose of Pfizer-BioNTech COVID-19 vaccine. Humoral response was evaluated by testing anti-SARS-CoV-2 Spike (S) Receptor Binding Domain (RBD) and anti-Nuclear (N) antibody titers, and evaluation of neutralizing ability by inhibition of RBD:ACE2 binding. Cellular immune response was evaluated by ELISpot, estimating IL2 and IFNγ secretion in response to pooled SARS-CoV-2 S or M peptides. Results Our cohort included 18 patients with predominantly antibody deficiency, 2 with combined immunodeficiency, 3 with immune-dysregulation, and 3 with other genetically defined diagnoses. 22/26 were receiving immunoglobulin replacement therapy. 18/26 developed specific antibody response and 19/26 showed S-peptide specific T-cell response. None of the patients reported significant adverse events. Conclusion Vaccinating IEI patients is safe, and most patients were able to develop vaccine specific antibody response, S-protein specific cellular response or both.

In late 2019 the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was 108 identified and described as causing a pneumonia outbreak, known as the Coronavirus Induced 109

Disease-19 (COVID-19) (1) . Emerging as a local outbreak in Wuhan, China, it had soon spread 110 to cause a pandemic of acute respiratory syndrome, which can result in significant morbidity and 111 mortality(2). So far, despite recommendations for potential intervention strategies (3), severely 112 affected patients benefit mostly from supportive treatment. Therefore, mass vaccination using 113 highly effective anti-SARS-CoV-2 vaccines, remains the best hope to protect against severe 114 disease (4,5), limit viral spread (6,7) and hopefully end the pandemic. 115

While data is accumulating to support the effectiveness and safety of the newly developed anti-116 SARS-CoV-2 vaccines, initial studies enrolled mostly healthy volunteers, whereas data regarding 117 defined patient populations is still being gathered. As such, patients with Inborn Errors of 118 Immunity (IEI) are of special interest for several reasons. First, recent reports have suggested 119 that IEI patients might be at an increased risk to develop severe 9) and can 120 therefore benefit from more 'aggressive' immunization effort. On the other hand, the underlying 121 immune abnormality might impair the ability of IEI patients to respond to the vaccine and to 122 develop anti-SARS-CoV-2 protective immunity, therefore questioning the benefit of the 123 vaccination approach. In view of this, characterizing the immune response of IEI patients 124 following SARS-CoV-2 vaccination is crucial, both for the understanding of their degree of 125 protection, and for formulating an optimal immunization regimen. Moreover, data gathered from 126 analyses of the immune response of IEI patients to the anti-COVID19 vaccine, could be relevant 127 to other patient populations, especially those with secondary and acquired immunodeficiency.

Anti-SARS-CoV-2 antibodies developed following infection, have been shown to possess 129 neutralizing activity both in-vitro and in-vivo (10-13) and a potential benefit of using 130 monoclonal neutralizing antibodies in patients with mild to moderate disease has been suggested 131 (14, 15) . Nevertheless, the longevity of the antibody response, and thus the duration of humoral 132

protection is yet unknown, with several studies suggesting a trend toward declining antibody 133 levels over time (16), and others showing persistence of RBD-specific memory B cells (17, 18) . 134

In parallel, several studies have highlighted the role of cellular immunity, and the long-term anti-135 SARS-CoV-2 T-cell response (19) . As such, effective T-cell response was shown to be 136 associated with milder COVID-19 (20,21), and robust and increasing cellular response was 137 shown to developed over time with specific anti-viral T-cells detected 6-8 month after infection 138 (18, 22) . Interestingly, T cells against the closely related SARS-CoV were detected as long as 11 139 years post recovery (23) while no SARS-CoV antigen-specific memory B cells or antibodies 140 were detected 6 years post infection (24). Therefore, while neutralizing antibodies play a role in 141 protection against SARS-CoV-2 and an orchestrated adaptive immunity can limit disease 142 severity (21), when estimating vaccine immunogenicity, one should evaluate both the humoral 143 and the cellular anti-vaccine immune response. Such an evaluation is even of greater importance 144 in IEI patients, most of whom suffer some level of impaired antibody production, and evaluation 145 of their post-vaccine antibody titers might give a false impression of unresponsiveness, thereby 146 preventing patients from getting vaccinated. 147

In this report we aimed to study a group of adult IEI patients, and evaluate their early humoral 148 and cellular immune response to Pfizer-BioNTech anti-COVID-19 vaccine. Based on our 149 analyses we are able to conclude that most IEI patients safely respond to the vaccine and should 150 therefore be vaccinated. 151

This study was approved by the Institutional Review Board of the Tel-Aviv Sourasky Medical 154

Center and was registered (NCT04724642). All adult patient with established IEI diagnosis, who 155 visited our clinic between the end of January and mid-March 2021 were offered to join the study. 156

After providing written informed consent, IEI patients and healthy controls were included in the 157 study. Participating donors received two doses of the mRNA-based Pfizer-BioNTech COVID19 158 vaccine three weeks apart, and samples were collected two weeks after the second vaccine dose. 159

For convalescent donors, samples were collected two weeks after recovering from COVID-19 160 (defined as 10 days following a positive SARS-CoV-2 RT-PCR test, and no symptoms for at 161 least 3 days). All consented subjects were included in this report and no subject was excluded. antibodies. Results were provided in arbitrary units (AU/ml) as was defined by the manufacturer, 179 ranging between 0-40,000AU/mL for anti-S antibodies (level>150AU/mL considered positive), 180 and relative light units (RLU) for anti-N antibodies (level of above 1.4RLU considered positive). 181

For serum ELISA, high-binding 96 well ELISA plates (Corning #9018) were coated with 1 183 µg/ml RBD antigen in PBS x1 overnight at 4 C. The following day, the coating was discarded, 184 washed with "wash buffer" containing PBS x1 and 0.05% Tween20, and the plates were blocked 185 for 2 hours at room temperature (RT) with 200 µl of "blocking buffer" containing PBS x1, 3% 186 BSA (MP Biomedicals), 20mM EDTA and 0.05% Tween20 (Sigma). Plasma samples were 187 diluted 4-fold in blocking buffer starting from 1:100 with seven consecutive dilutions (1:100, 188 1:400, 1:1600, 1:6400 etc..) and incubated for 1 hour at RT. Plates were then washed 3 times 189 with washing buffer before adding secondary anti-IgG (Jackson ImmmunoResearch 109-035-190 088) antibodies conjugated to horseradish peroxidase (HRP) diluted 1:5000 in blocking buffer, 191 and incubated for 45 min at RT. Following four additional washes with "wash buffer" and last 192 final wash with PBS x1, 100 µl of TMB/E (3,3',5,5'-tetramethylbenzidine, abcam) diluted 1:2 in 193 DDW was added to each well and the absorbance was read after 25 min at 650 nm (BioTek 800 194 TS). Positive and negative controls were added to each plate and the signal was normalized to 195 the controls for each plate. 196

For ACE2:RBD inhibition ELISA, high-binding 96 well plates were coated with 2 µg/ml human 199 ACE2 in PBS x1 overnight at 4 C. The next day, plates were washed and blocked with blocking 200 buffer for 2 hours at RT. Plasma samples were diluted 2-fold in blocking buffer starting from 201 1:10 and incubated with biotinylated RBD for 30 min at RT. The RBD-plasma mix was then 202 applied to the ACE2 coated plates and incubated for 20 min, followed by three washes. (Table I) patients showed a wide range of anti-S antibody titers, ranging between undetectable levels to 286 normal-to-high titers (Supp Table I , Fig 1A and Fig 2A) . Out of the 26 IEI patients, 18 patients 287 were tested positive for anti-S antibodies. As expected, 'B-negative' XLA patients (and a non-288 IEI rituximab-treated patient), failed to produce anti-S antibodies (2.86±1.18). After excluding 289 the four XLA patients, 18 out of 22 patients (81.8%) developed anti-S antibodies, of which 13 290 where on immunoglobulin replacement therapy for diagnosis of CVID. The four non-XLA IEI 291 patients who were tested negative for anti-S antibodies included one ALPS-like patient, one CID 292 patient and two CVID patients. Dissecting the different IEI patient groups (Fig 2A) to anti-N antibodies (Supp Table I and Supp Fig 1) . 310 ELISA: The SARS-CoV-2 Spike protein RBD is the part of the virus responsible for viral entry 311 through attachment to ACE2 receptor (26). In view of that, RBD was previously identified as 312 one of the key determinants for neutralizing antibodies, with high correlation between anti-RBD 313 antibody titers and serum neutralization (27,28) . Therefore, we next asked what were the levels 314 of anti-RBD IgG in the plasma of IEI donors. For this purpose, we serially diluted serum samples 315 were incubated with plate-bound RBD, and area under curve was calculated for each sample. In 316 accordance with the commercial anti-S test results, healthy vaccinated individuals (N=11) had 317

higher titers compared to convalescent donors (N=12), including patients recovering from 318 severe, moderate and mild COVID-19 (Fig 1B,D) (Fig 2B) . Next, we tested the ability of the plasma samples to inhibit 324 SARS-CoV-2 attachment to the host cells by assessing the level of serum antibodies that 325 interfere with the RBD:ACE2 interaction (13). As we previously reported, anti-RBD IgG level 326 correlated well with the ability of serum samples to inhibit RBD:ACE2 binding in a competitive 327 ELISA assay (Fig 1C,E and 2C) . When excluding XLA patients, 18 out of 21 (85.7%) IEI 328 patients showed some level of RBD:ACE2 inhibition, suggesting that the majority of vaccinated infection. Here too, younger CVIDs showed higher average RBD:ACE2 inhibition compared to 331 older CVIDs (Ave of 68.98% vs 21.98%, p=0.019) (Fig 2C) . Table I and Fig  355   3A ,B). The 7 non-responders included one ALPS-like patient, two NFKB1-HI patients, two 356 young CVIDs and two older CVIDs. Only one of these non-responders (ALPS-Like patient) also 357 failed to produce anti-S antibodies. The remaining six patients were tested positive for anti-S 358 antibodies, although three of them had a low-positive anti-S antibody titers of below 400AU/mL 359 (Supp Table I) . 360

Similar to what we observed in the antibody assays, here too, the vaccine induced a strong 361 cellular response following vaccination, and a trend toward statistical-significance when 362 comparing convalescent individuals to healthy vaccinated donors (average number of spots: 363 6.25±3.5 vs 13.2±6.79. p=0.079) (Fig 3A) . 364

In contrast to the observed when analyzing the humoral response data, there were no statistically 365 significant differences between healthy vaccinated donors and IEI patients at any age group, with 366 an average number of spots of 13.2±6.79 vs 23.14±35.36; p=0.356 for all IEIs (Fig 3A) While the response to M-peptides was mostly limited to convalescent individuals (Supp Fig  370   4A ,B), we were able to identify two healthy vaccinated individuals who responded to M-peptides 371 stimulation (with 31 and 8 spots, Supp Fig 5A,B) but tested negative for anti-N antibodies. This 372 response could be either due to cross reactivity, non-specific activation or possible 373 convalescence from asymptomatic COVID-19. In addition, one CID patient had a very strong 374 response to both S and M peptides (67 and 161 spots, respectively, Supp Fig 6) but was negative absolute lymphocyte count of ~300/L, therefore, non-specific activation was suspected, 377 although we do not have an unstimulated control to confirm it. All three subjects denied history 378 of symptomatic COVID-19 and never had a positive RT-PCR test for SARS-CoV-2 RNA. 379 Fig 6) . 397

Despite that, the father showed good antibody response (titer of 7102.7 AU/mL), while his 398 daughter had a weak positive response (titer of 202.5 AU/mL; positive >150 AU/mL). While 399 NFB1-HI patients can present with a wide range of clinical symptoms (29), the absent T cell 400 response in these two family members suggests that the vaccine response in patients with NFB 401 pathway defects should be further evaluated. 402 STAT1-GOF: Our cohort included one STAT1-GOF patient with history of chronic 403 mucocutaneous candidiasis and recurrent oral ulcers, who is on low-dose ruxolitinib treatment 404 (5mg BID). Evidence suggests that STAT1-GOF mutations can result in enhanced type I IFN 405 response (30,31) , therefore, there is a theoretical concern that STAT1-GOF patients would 406 suffer more significant adverse events following mRNA-based vaccine, with exacerbation of 407 underlying autoimmunity or development of new inflammatory symptoms. Despite that, our 408 patient did not report any significant adverse events, other than transient mild weakness after the 409 second vaccine. Interestingly, he developed the highest anti-S antibody titer in our cohort 410 (>29,000AU/mL). 411 T-cell non-responders: As mentioned above, seven IEI patients failed to show anti-S cellular 412 response on our ELISpot assay (Supp. Fig 6 & 7) . These include two NFB1-HI patients, one 413 ALPS-like patient and four CVID patients. There was no common T-cell phenotyping feature 414 shared by all the non-responder individuals, other than inverted CD4 to CD8 ratio in 4 out 5 415 available pre-vaccine T-cell phenotyping samples, all in the presence of normal absolute 416 lymphocyte counts (Fig 5) . 

A pneumonia outbreak

Human 588 STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and (32)

Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Influence of immune aging on vaccine 593 responses

Two X-linked 595 agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

A possible role 598 for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Dendritic and T cell response to influenza 601 is normal in the patients with X-linked agammaglobulinemia

Table I: Patient characteristics: aHUS -Atypical hemolytic uremic syndrome

CID-Combined 609 immunodeficiency, Con. -Convalescent, DLBCL -Diffuse large B-cell lymphoma, GI -610 gastrointestinal, IBD -Inflammatory bowel disease, IgRT -Immunoglobulin replacement 611 therapy, HTN -hypertension

Hypogammaglobulinemia * Genetically confirmed but patient preferred to not publish the 615 pathogenic variant

Here too, younger CVID patients had higher anti-RBD 641 titers and showed higher inhibition compared to older CVIDs. For statistical analysis, unpaired 642 student's t-test between younger an older CVID groups was performed. 643 treated donors. Images of seven younger (age<50) healthy vaccinated individuals (B) and five 660 convalescent donors (C) are shown as control

IgG1/IgG3 deficient patient (IEI-Con). HV-Healthy vaccinated